231 related articles for article (PubMed ID: 21733760)
1. Use of rosiglitazone and pioglitazone immediately after the cardiovascular risk warnings.
Jain R; Mullins CD; Lee H; Wong W
Res Social Adm Pharm; 2012; 8(1):47-59. PubMed ID: 21733760
[TBL] [Abstract][Full Text] [Related]
2. The thiazolidinediones rosiglitazone and pioglitazone and the risk of coronary heart disease: a retrospective cohort study using a US health insurance database.
Ziyadeh N; McAfee AT; Koro C; Landon J; Arnold Chan K
Clin Ther; 2009 Nov; 31(11):2665-77. PubMed ID: 20110009
[TBL] [Abstract][Full Text] [Related]
3. Rosiglitazone and pioglitazone utilization from January 2007 through May 2008 associated with five risk-warning events.
Starner CI; Schafer JA; Heaton AH; Gleason PP
J Manag Care Pharm; 2008; 14(6):523-31. PubMed ID: 18693776
[TBL] [Abstract][Full Text] [Related]
4. Incidence of cardiovascular events in which 2 thiazolidinediones are used as add-on treatments for type 2 diabetes mellitus in a Taiwanese population.
Wang CC; Chen WL; Kao TW; Chang YW; Loh CH; Chou CC
Clin Ther; 2011 Dec; 33(12):1904-13. PubMed ID: 22118894
[TBL] [Abstract][Full Text] [Related]
5. Comparisons of rosiglitazone versus pioglitazone monotherapy introduction and associated health care utilization in Medicaid-enrolled patients with type 2 diabetes mellitus.
Balkrishnan R; Arondekar BV; Camacho FT; Shenolikar RA; Horblyuk R; Anderson RT
Clin Ther; 2007 Jun; 29(6 Pt 1):1306-15. PubMed ID: 18036392
[TBL] [Abstract][Full Text] [Related]
6. Thiazolidinediones in type 2 diabetes: a cardiology perspective.
Khanderia U; Pop-Busui R; Eagle KA
Ann Pharmacother; 2008 Oct; 42(10):1466-74. PubMed ID: 18698014
[TBL] [Abstract][Full Text] [Related]
7. Changes and predictors for change to thiazolidinedione prescribing in UK primary care following the rosiglitazone safety warning.
Hall GC; Smith HT; Curtis B; McMahon AD
Int J Clin Pract; 2011 May; 65(5):586-91. PubMed ID: 21489082
[TBL] [Abstract][Full Text] [Related]
8. Comparison of cardiovascular outcomes in elderly patients with diabetes who initiated rosiglitazone vs pioglitazone therapy.
Winkelmayer WC; Setoguchi S; Levin R; Solomon DH
Arch Intern Med; 2008 Nov; 168(21):2368-75. PubMed ID: 19029503
[TBL] [Abstract][Full Text] [Related]
9. Risk of stroke with thiazolidinediones: a ten-year nationwide population-based cohort study.
Lu CJ; Sun Y; Muo CH; Chen RC; Chen PC; Hsu CY
Cerebrovasc Dis; 2013; 36(2):145-51. PubMed ID: 24029780
[TBL] [Abstract][Full Text] [Related]
10. Development of heart failure in Medicaid patients with type 2 diabetes treated with pioglitazone, rosiglitazone, or metformin.
Breunig IM; Shaya FT; McPherson ML; Snitker S
J Manag Care Spec Pharm; 2014 Sep; 20(9):895-903. PubMed ID: 25166288
[TBL] [Abstract][Full Text] [Related]
11. Utilization and costs for compliant patients initiating therapy with pioglitazone or rosiglitazone versus insulin in a Medicaid fee-for-service population.
Kalsekar I; Iyer S; Mody R; Rajagopalan R; Kavookjian J
J Manag Care Pharm; 2006 Mar; 12(2):121-9. PubMed ID: 16515370
[TBL] [Abstract][Full Text] [Related]
12. Pioglitazone and the risk of myocardial infarction and other major adverse cardiac events: a meta-analysis of randomized, controlled trials.
Nagajothi N; Adigopula S; Balamuthusamy S; Velazquez-Cecena JL; Raghunathan K; Khraisat A; Singh S; Molnar J; Khosla S; Benatar D
Am J Ther; 2008; 15(6):506-11. PubMed ID: 19127132
[TBL] [Abstract][Full Text] [Related]
13. Coronary heart disease outcomes in patients receiving antidiabetic agents.
McAfee AT; Koro C; Landon J; Ziyadeh N; Walker AM
Pharmacoepidemiol Drug Saf; 2007 Jul; 16(7):711-25. PubMed ID: 17551989
[TBL] [Abstract][Full Text] [Related]
14. Risk of acute myocardial infarction in patients treated with thiazolidinediones or other antidiabetic medications.
Stockl KM; Le L; Zhang S; Harada AS
Pharmacoepidemiol Drug Saf; 2009 Feb; 18(2):166-74. PubMed ID: 19109802
[TBL] [Abstract][Full Text] [Related]
15. Adherence to a fixed-dose combination of rosiglitazone maleate/metformin hydrochloride in subjects with type 2 diabetes mellitus: a retrospective database analysis.
Vanderpoel DR; Hussein MA; Watson-Heidari T; Perry A
Clin Ther; 2004 Dec; 26(12):2066-75. PubMed ID: 15823770
[TBL] [Abstract][Full Text] [Related]
16. Distal upper and lower limb fractures associated with thiazolidinedione use.
Jones SG; Momin SR; Good MW; Shea TK; Patric K
Am J Manag Care; 2009 Aug; 15(8):491-6. PubMed ID: 19670952
[TBL] [Abstract][Full Text] [Related]
17. Association between congestive heart failure and hospitalization in patients with type 2 diabetes mellitus receiving treatment with insulin or pioglitazone: a retrospective data analysis.
Rajagopalan R; Rosenson RS; Fernandes AW; Khan M; Murray FT
Clin Ther; 2004 Sep; 26(9):1400-10. PubMed ID: 15531002
[TBL] [Abstract][Full Text] [Related]
18. Pioglitazone is a valid alternative to rosiglitazone.
Derosa G
Am J Cardiovasc Drugs; 2011 Dec; 11(6):357-62. PubMed ID: 21950735
[TBL] [Abstract][Full Text] [Related]
19. Antidiabetic prescribing trends and predictors of thiazolidinedione discontinuation following the 2007 rosiglitazone safety alert.
Hurren KM; Taylor TN; Jaber LA
Diabetes Res Clin Pract; 2011 Jul; 93(1):49-55. PubMed ID: 21440324
[TBL] [Abstract][Full Text] [Related]
20. Geographic Variation in Rosiglitazone Use Surrounding FDA Warnings in the Department of Veterans Affairs.
Ahuja V; Sohn MW; Birge JR; Syverson C; Budiman-Mak E; Emanuele N; Cooper JM; Huang ES
J Manag Care Spec Pharm; 2015 Dec; 21(12):1214-34. PubMed ID: 26679970
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
